Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21261831 | 0.84 | TDP1 (0.42) | TDP1CA1CA2CA7MEN1 | |
| SCHEMBL1359163 | 0.83 | TDP1 (0.47) | TDP1CA1CA2CA7MEN1 | |
| SCHEMBL16775592 | 0.83 | TDP1 (0.43) | TDP1CA1CA2CA7MEN1 | |
| SCHEMBL55502 | 0.82 | TDP1 (0.46) | TDP1CA1CA2CA7MEN1 | |
| SCHEMBL4616898 | 0.82 | CA1 (0.42) | TDP1CA1CA2CA7MEN1 | |
| SCHEMBL6823074 | 0.82 | TDP1 (0.46) | TDP1CA1CA2CA7MEN1 | |
| SCHEMBL25247785 | 0.80 | TDP1 (0.40) | TDP1CA1CA2CA7MEN1 | |
| SCHEMBL16906203 | 0.80 | TDP1 (0.48) | TDP1CA1CA2CA7MEN1 | |
| SCHEMBL12775693 | 0.80 | POLB (0.43) | TDP1CA1CA2CA7MEN1 | |
| SCHEMBL30489694 | 0.80 | TDP1 (0.40) | TDP1CA1CA2CA7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 603 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA AS (DK) | 2026-02-19 | — | — | US | disclosed |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12391644-B2 | Potassium channel inhibitors | SANIONA A/S (DK) | 2025-08-19 | — | — | US | disclosed |
| EP-3941903-B1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA AS (DK) | 2025-07-16 | — | — | EP | disclosed |
| US-20250214954-A1 | METHODS OF TREATING HIV USING TRITERPENE DERIVATIVES | HETERO LABS LIMITED (IN) | 2025-07-03 | — | — | US | disclosed |
| US-12324802-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-04-17 | — | — | US | disclosed |
| US-12275712-B2 | Triterpene derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2025-04-15 | — | — | US | disclosed |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2025-03-20 | — | — | US | disclosed |
| US-4843072-A | Antihypertensive pyridazinone aminoisopropanol derivatives | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1989-06-27 | — | — | US | disclosed |
| EP-0259835-A2 | Pyridazinone derivatives | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1988-03-16 | — | — | EP | disclosed |
| US-4698231-A | Sweetening with L-aminodicarboxylic acid amides | GENERAL FOOD CORPORATION (US) | 1987-10-06 | — | — | US | disclosed |
| US-4654439-A | FOOD SWEETENERS | GENERAL FOODS CORPORATION (US) | 1987-03-31 | — | — | US | disclosed |
| US-4650688-A | DIPEPTIDES | GENERAL FOODS CORPORATION (US) | 1987-03-17 | — | — | US | disclosed |
| EP-0203539-A1 | L-Aminodicarboxylic acid amides of alkoxyalkylamines and an edible composition containing same | GENERAL FOODS CORPORATION (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0203540-A1 | L-Aminodicarboxylic acid amides of substituted amines and a composition containing the same | GENERAL FOODS CORPORATION (US) | 1986-12-03 | — | — | EP | disclosed |
| US-4622232-A | L-aminodicarboxylic acid alkanes | GENERAL FOODS CORPORATION (US) | 1986-11-11 | — | — | US | disclosed |
| US-4622418-A | LOW CALORIE SWEETENERS | GENERAL FOODS CORPORATION (US) | 1986-11-11 | — | — | US | disclosed |
| US-4603011-A | ARTIFICIAL SWEETRENERS | GENERAL FOODS CORPORATION (US) | 1986-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391644-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | TDP1 2290/4885CA1 2389/4885CA2 272/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | TDP1 3446/4885CA1 2449/4885CA2 730/4885 |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | TDP1 1621/4885CA1 4733/4885CA2 4430/4885 |
| US-12275712-B2 | Triterpene derivatives as HIV inhibitors | CCR5, CYP51A1, CYP4A11 | TDP1 2732/4885CA1 4825/4885CA2 4635/4885 |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | TDP1 1621/4885CA1 4733/4885CA2 4430/4885 |
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SCN10A, KCNK10, KCNJ2 | TDP1 3540/4885CA1 1345/4885CA2 183/4885 |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | TDP1 1371/4885CA1 4739/4885CA2 4350/4885 |
| US-20250214954-A1 | METHODS OF TREATING HIV USING TRITERPENE DERIVATIVES | CCR5, HSD17B7, CYP51A1 | TDP1 3648/4885CA1 4840/4885CA2 4761/4885 |
| US-12324802-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1G, SCNN1B | TDP1 4655/4885CA1 4878/4885CA2 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.